HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 01-20-2015, 05:26 PM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Thumbs up INCREDIBLE MILESTONE--trial of less toxic regimen in <3cm her2+ early bc ~100% 3yrdfs

dfs=invasive disease free survival

from Med Page Today

Oncology/Hematology 01.07.2015

Less Toxic Breast Ca Regimen Deemed Successful

Study finds 98.7% rate of 3-year freedom from invasive recurrence or death.




by Charles Bankhead
Staff Writer, MedPage Today


Patients with small, node-negative, HER2-positive breast cancers had a 3-year survival approaching 100% with adjuvant paclitaxel and trastuzumab (Herceptin).

Note that safety results were generally good, as relatively few patients had grade 3 peripheral neuropathy, heart failure, or asymptomatic declines in left ventricular ejection fraction.

Patients with small, node-negative, HER2-positive breast cancers had a 3-year survival approaching 100% with adjuvant paclitaxel and trastuzumab (Herceptin), a multicenter, prospective trial showed.

The 406 patients included in the study had 3-year invasive disease-free survival (IDFS) of 98.7%. After excluding contralateral HER2-negative recurrences and nonbreast cancers, investigators identified seven disease-specific recurrences.


Safety results were generally good, as relatively few patients had grade 3 peripheral neuropathy, heart failure, or asymptomatic declines in left ventricular ejection fraction (LVEF), as reported online in the New England Journal of Medicine.

"The regimen we used in this study was associated with patient outcomes that were better than expected on the basis of historical data," Eric Winer, MD, of Dana-Farber Cancer Institute in Boston, and co-authors said in conclusion. "However, the study does not provide data to support the use of trastuzumab-based chemotherapy in all patients with small HER2-positive tumors, and there will be many patients with T1a disease and some with T1b disease who will decide with their physicians to avoid the toxic effects of a trastuzumab-based regimen."

The findings may help establish a standard of care for the subgroup of patients with small, node-negative, HER2-positive tumors, Winer said in a statement. Currently, no consensus exists about the most appropriate systemic therapy for the subgroup.

"This study demonstrates that a combination of lower-intensity chemotherapy and trastuzumab -- which is associated with fewer side effects than traditional chemotherapy regimens -- is an appealing standard of care for this group of patients," said Winer.

A chemotherapy-free regimen for such patients might even be possible for these patients, said Charles Shapiro, MD, of Dubin Breast Center at Mount Sinai Hospital in New York City.(my highlight...lani)


"The results beg the question: Is chemotherapy necessary? What about just trastuzumab alone in this stage I population?" Shapiro asked. "Two-thirds of the study population was also estrogen receptor-positive and also received antiestrogens, like tamoxifen, or aromatase inhibitors. Could this group of patients be treated with antiestrogens and trastuzumab?"

Winer and colleagues reported data from a trial designed to determine whether adjuvant paclitaxel-trastuzumab could achieve a low rate of recurrence with less toxicity as compared with conventional adjuvant chemotherapy regimens. Investigators in the nonrandomized, single-arm trial enrolled patients with HER2-positive, node-negative tumors <3 cm in size.

All patients received paclitaxel and trastuzumab, administered weekly for 12 weeks. At that point, patients could continue weekly trastuzumab or switch to a higher dose of trastuzumab administered every 3 weeks. Maintenance trastuzumab continued for 40 weeks.

Patients who underwent lumpectomy received either partial-breast or whole-breast irradiation, and patients with hormone receptor-positive tumors also received adjuvant endocrine therapy.

Investigators assessed LVEF function by echocardiography or MUGA scans at 12 weeks, 6 months, and 1 year. Trastuzumab was withdrawn if a patient developed grade 3 or 4 LVEF dysfunction, and dose interruptions came into play for patients who had prespecified declines in LVEF function.

The trial had a primary endpoint of freedom from invasive disease (recurrent or new invasive disease) and death from any cause. A 3-year event rate of 9.2% was defined in the trial protocol as unacceptable and an event rate ≤5% as successful. The data and safety monitoring board ended the trial after a third interim analysis that occurred after 1,316 patient-years of follow-up. The published results reflected 1,605 patient-years of follow-up.

Patients' median age was 55, and 272 (67%) had HR-positive tumors. Half of the patients had tumors ≤1 cm, and 9% had tumors that were 2 to 3 cm at the greatest dimension.

The authors reported that 356 (87.7%) of patients completed the planned 52 weeks of therapy. The median follow-up was 4.0 years and ranged to 6.2 years.

Twelve protocol-defined primary events were recorded: two patients with distant recurrence, four with local or regional recurrence, four contralateral breast cancer (three of which were HER2-negative), and two deaths (one resulting from rapidly progressing ovarian cancer and one resulting from a stroke). Additionally, four patients had new diagnoses of nonbreast cancer that was not considered relapsed/recurrent disease, as well as four patients who had new diagnoses of ductal carcinoma in situ, also not included in calculations of the primary endpoint.

The 3-year IDFS of 98.7% exceeded the 95% threshold prespecified as the definition of a successful trial (P<0.001).

During the 12 weeks of combination therapy, 14 (3.2%) patients had one or more episodes of grade 3 neuropathy; no grade 4 neurotoxicity was reported. Two patients (0.5%) had grade 3 systolic left ventricular dysfunction, and both recovered after discontinuation of trastuzumab. Additionally, 13 (3.2%) patients had clinically significant declines in LVEF necessitating interruption of trastuzumab treatment. Seven patients had grade 3/4 allergic reactions to study medication.

The study was supported by Genentech and by Susan G. Komen for the Cure.

Winer disclosed a relevant relationship with Genentech. One or more co-authors disclosed relevant relationships with Genentech, Roche, sanofi, Wyeth/Pfizer, Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Medigene, AstraZeneca, and PAM50 Bioclassifier.

Reviewed by Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner
last updated 01.08.2015

Primary Source

New England Journal of Medicine

Source Reference: Tolaney SM, et al "Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer" N Engl J Med 2015; DOI: 10.1056/NEJMoa1406281.
Lani is offline   Reply With Quote
Old 01-20-2015, 06:29 PM   #2
sassy
Senior Member
 
sassy's Avatar
 
Join Date: Sep 2005
Location: Mountains of Virginia
Posts: 2,267
Images: 4
Re: INCREDIBLE MILESTONE--trial of less toxic regimen in <3cm her2+ early bc ~100% 3y

Whoop! Whoop!

Thanks for posting this Lani!!
__________________
Rhonda (Sassy)
dx age 45
DX 2/15/05 Stage IIb (at surgery)restaged IIIa
Left mast .9cm tumor 5 of 14 nodes
Triple Positive
4 DD A/C
12 Taxol/Herceptin
33Rads
Strange infect mast site one year aft surg, hosp 1 wk
Herceptin for total of 18 months
Lupron Monthly 4 yrs
Neurontin for aches, pains and hot flashes(It works!)
Ovaries removed 11/09 stop Lupron and Neurontin
Arimidex 6 yrs (tried Femara, no SE improvement)
Tried Exemestane-hips got so bad could hardly walk
Back to Arimidex for year seven
Zometa 2X Annual for 7years, Lasix
Stop Arimidex 5/13
Stop Zometa 7/13-Bi-lateral Stress Fractures in Femurs from Zometa
5/14 Start Tamoxifen
3/15 Stem cell transplant to stimulate femur bone growth/healing
5/15 Complete fracture of right femur/Titanium rods both femurs
9/16 Start Evista stopTamoxifen
3/17 Stop Evista--unwelcome side effects!
NED and no meds.......
14YEARS NED!
sassy is offline   Reply With Quote
Old 01-21-2015, 05:22 PM   #3
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Re: INCREDIBLE MILESTONE--trial of less toxic regimen in <3cm her2+ early bc ~100% 3y

http://www.dana-farber.org/Newsroom/...st-tumors.aspx
Lani is offline   Reply With Quote
Old 01-22-2015, 09:52 PM   #4
suzan w
Senior Member
 
suzan w's Avatar
 
Join Date: Sep 2005
Location: Naples FL
Posts: 1,744
Re: INCREDIBLE MILESTONE--trial of less toxic regimen in <3cm her2+ early bc ~100% 3y

Yes indeedy...incredible!!
__________________
Suzan W.
age 54 at diagnosis
5/05 suspicious mammogram-left breast
5/05 biopsy-invasive lobular carcinoma with LCIS,8mm tumor,stage 1 grade 2, ER+ PR+ Her2+++
6/14/05 bilateral mastectomy, node neg. all scans neg.
Oncotype DX-high risk
8/05-10/05 4 rounds A/C
10/05 -10/06 1 yr. herceptin
arimidex-5 years
2/14/08 started daily self administered injections..FORTEO for severe osteoporosis
7/28/09 BRCA 1 negative BRCA2 POSITIVE
8/17/09 prophylactic salpingo-oophorectomy
10/15/10 last FORTEOinjection
RECLAST infusion(ostoeporosis)
6/14/10 5 year cancerversary!
8/2010-18%increase in bone density!
no further treatments
Oncologist says, "Go do the Happy Dance"
I say,"What a long strange trip its been"
'One day at a time'
6-14-2015. 10 YEAR CANCERVERSARY!
7-16 to 9-16. Extensive (and expensive) dental work done to save teeth. Damage from osteoporosis and chemo and long term bisphosphonate use
6-14-16. 11 YEAR CANCERVERSARY!!
7-20-16 Prolia injection for severe osteoporosis
2 days later, massive hive outbreak. This led to an eventual dx of Chronic Ideopathic Urticaria, an auto-immune disease from HELL.
6-14-17 12 YEAR CANCERVERSARY!!
still suffering from CIU. 4 hospitilizations in the past year

as of today, 10-31-17 in remission from CIU and still, CANCER FREE!!!
6-14-18 13 YEAR CANCERVERSARY!! NED!!
suzan w is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 12:43 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter